Compare Revvity Inc (RVTY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 6.7× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| RVTY | SGOV | |
|---|---|---|
Market Cap | $16.98B | $114.40B |
Volume | 1,456,900 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $100.72 |
52-Week Low | $82.26 | $100.28 |
Typical Hold Time | 12 Days | 50 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.515 with minimal daily movement, reflecting its stable nature. The technical picture is bearish according to moving averages, though oscillators are neutral. Recent corporate actions show consistent dividend payments. Market sentiment is influenced by broader bond market volatility and institutional positioning shifts.
The outlook for SGOV is tied to short-term Treasury yields and Federal Reserve policy. Opportunities include stability and income, but risks involve rising interest rates and institutional selling. Investors should weigh the ETF's defensive role against potential yield compression in a changing rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
